PledPharma AB Company Announcement PledPharma's patent application approved and issued in USA Stockholm, 2013-02-20 10:19 CET (GLOBE NEWSWIRE) -- PledPharma today announces that it has received patent approval for the US market. This is the first patent in a series of worldwide applications aiming to achieve exclusive and broad commercial rights for manufacturing and use of PLED compounds, including among others PledOx™ (calmangafodipir). PLED-compounds protect against serious side effects of chemotherapy drugs during cancer treatment. - “This means a significant competitive advantage for PledPharma and its brands, says Jacques Näsström, CEO of PledPharma”. This particular patent "Compounds for Use in the Treatment of Cancer" covers, as the title reveals, use of PLED compounds in cancer treatment. - “This is an important milestone for PledPharma, says Jan Olof G. Karlsson, responsible for patents and one of the founders of PledPharma. To achieve patent approval takes time and differs between various countries and regions (for more details see PledPharma’s website). In case of the present patent, the first application was filed already in December 2007 and is at present a matter of examination and prosecutions in the various countries and regions. PledPharma has thereafter filed several other applications. As US is the most important market for drugs as those developed by PledPharma, it is indeed satisfying that we have achieved approval in the US as the first country, says Jan Olof.” For further information please contact: Jacques Näsström, CEO, +46 737 130 979, [email protected] Jan Olof G. Karlsson, Senior Scientist, +46 733 304 624, [email protected] About PledPharma PledPharma is a Swedish specialty pharma company that develops PledOx™ (calmangafodipir) for prevention of severe chemotherapy-induced side effects in cancer patients. Due to these side effects optimal treatment cannot be carried out. The current market for supportive cancer care is some SEK 72 billion. PledOx protects normal cells against oxidative stress. It belongs to a group of compounds named lowMEM (low Molecular Enzyme Mimetics), and mimics the enzyme Manganese SuperOxide Distmutase (MnSOD) – the most important endogenous cellular protectant against devastating oxidative stress. Oxidative stress is a condition caused by harmful oxygen/nitrogen molecules, e.g., as a result of chemotherapy treatment. The company is also evaluating opportunities of using PLED substances in other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For further information, please visit www.pledpharma.se
